parallel randomized trial

NCT01795248

The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus

Design

Randomized: 104
Start year: 2012
Treatment: 52 weeks, follow-up 52 weeks
Countries: Denmark (1 sites)
Sponsor: Tina Vilsboll (investigator initiated; Novo Nordisk grant and drug) (mixed)
Eligibility: women with prior gestational diabetes; no diabetes; overweight or obese

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Placebo Placebo	lifestyle: not reported		45
A2	Liraglutide 1.8 mg subcutaneous once daily Liraglutide 1.8 mg	lifestyle: not reported		37

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Placebo A1	Liraglutide 1.8 mg subcutaneous once daily A2
age	mean (years)	38.3	38.8
bmi	mean (kg/m2)	30.6	32.1
female	n	45	37
hba1c	mean (percent)	5.1	5.1
sbp	mean (mmHg)	128	125
waist	mean (cm)	104	104
weight	mean (kg)	83.9	89.0

2 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Systolic blood pressure change (2 lines; O05)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
52.18	A1	change	-6.9 mmHg		-10.1 to -3.7	45	not stated; completers; R0007651:Table 1
52.18	A2	change	-6.4 mmHg		-10.0 to -2.9	37	not stated; completers; R0007651:Table 1